KardiaAI vs EchoNext
AI Verdict
Choose KardiaAI if…
Choose KardiaAI if you need an AI-powered ECG analysis library for real-time detection of common cardiac arrhythmias like AFib, bradycardia, and tachycardia, particularly for ambulatory or personal ECG devices. It's ideal for integrating into existing mobile health platforms or for remote patient monitoring where immediate rhythm interpretation is crucial.
View KardiaAI →Choose EchoNext if…
Choose EchoNext if you require an AI tool to analyze standard 12-lead ECGs for the detection of hidden structural heart diseases, such as heart failure, valve disease, and pulmonary hypertension. This tool is best suited for clinical settings, from major hospitals to community practices, where early, non-invasive screening for complex cardiac conditions can inform further diagnostic imaging like echocardiography.
View EchoNext →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | KardiaAI | EchoNext |
|---|---|---|
| Pricing | Subscription-based for integrated services | Starts at $600/month |
| Deployment | Software as a Medical Device (SaMD), API library integrated into mobile apps and web platforms | Available through the OpenEvidence clinical decision support platform. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | 1 AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
KardiaAIKardiaAI, integrated into AliveCor's KardiaMobile devices and app, offers a highly user-friendly experience for personal ECG monitoring. Users can easily record 30-second ECGs, receive instant analysis, and share recordings with their physicians via email or the KardiaPro platform. EchoNext, while available through the OpenEvidence platform, is primarily an API library for integration into other systems, suggesting a less direct user interface for the end-user.
Clinical Value
EchoNextEchoNext demonstrates superior clinical value by detecting hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, from standard ECGsu2014conditions traditionally requiring more expensive and complex echocardiograms. Studies show EchoNext's higher accuracy (77%) compared to cardiologists (64%) in identifying structural heart problems. While KardiaAI offers detection of various cardiac arrhythmias, EchoNext's ability to identify underlying structural issues represents a more foundational and potentially life-saving diagnostic advancement.
Pricing & Value
KardiaAIKardiaAI offers transparent, subscription-based pricing for its integrated services, with clear monthly and annual options ranging from $13.99/month to $199/year. This makes its value proposition immediately accessible and easy to compare. EchoNext's pricing starts at $600/month with tiered plans and additional fees, which, while detailed, represents a significantly higher entry cost and potentially more complex pricing structure for individual practices or smaller institutions.
Enterprise Readiness
TieBoth tools demonstrate strong enterprise readiness. KardiaAI is an API library designed for integration into mobile apps and web platforms, and AliveCor's KardiaPro platform supports integration into Electronic Health Records (EHR) systems like EPIC. EchoNext is deployed through the OpenEvidence clinical decision support platform, which is used by a large number of U.S. physicians, indicating broad accessibility and integration potential within existing clinical workflows. Both are FDA-cleared and HIPAA compliant, further supporting their readiness for enterprise adoption.
Innovation
EchoNextEchoNext represents a significant innovation by being the world's first FDA-cleared AI tool to detect hidden structural heart disease, including heart failure and valve disease, directly from standard ECGs. This addresses a critical gap in early detection for conditions that traditionally require more advanced imaging. While KardiaAI offers a comprehensive suite of arrhythmia detections and has pioneered personal ECG technology, EchoNext's capability to identify underlying structural issues from a routine, inexpensive test is a more groundbreaking advancement in cardiology.
Support & Docs
KardiaAIKardiaAI, through AliveCor, provides readily available user manuals for its KardiaMobile devices and app, which include troubleshooting guides and direct contact information for technical support via email. The availability of these resources directly to end-users and healthcare professionals suggests a robust support system. While EchoNext is deployed via the OpenEvidence platform, specific details regarding its direct support and documentation for end-users or integrating partners are not as explicitly detailed in the provided information.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | KardiaAI | EchoNext |
|---|---|---|
| Name | KardiaAI | EchoNext |
| Company | AliveCor | Pathway Labs |
| Description | FDA-cleared AI software library for analyzing ambulatory ECG rhythms, detecting various cardiac conditions like AFib, bradycardia, and tachycardia. | FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. |
| Key Features (ECG Analysis) | AI-powered ECG analysis library; Detection of atrial fibrillation, bradycardia, tachycardia, and normal sinus rhythm; Detection of Sinus Rhythm with Premature Ventricular Contractions (PVCs); Detection of Sinus Rhythm with Wide QRS; Detection of Sinus Rhythm with Supraventricular Ectopy (SVE); ECG noise filtering and noisy ECG detection; API library for integration into other ECG devices and software; Medical-grade accuracy for heart rhythm data | AI-powered ECG analysis; Detection of hidden structural heart disease; Identifies heart failure risk; Screens for valve disease; Detects pulmonary hypertension indicators; Utilizes standard 12-lead ECGs; FDA-cleared technology; Non-invasive diagnostic support |
| Specialties | Cardiology, Emergency Medicine, Internal Medicine | Cardiology, Family Medicine, Hospital Medicine, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring KardiaAI and EchoNext.
Frequently Asked Questions
More Comparisons
More matchups featuring KardiaAI or EchoNext
Backers
Who funded each tool's parent company.